Report cover image

Global Oral Transmucosal Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 199 Pages
SKU # APRC20360639

Description

Summary

According to APO Research, the global Oral Transmucosal Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Oral Transmucosal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Oral Transmucosal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Oral Transmucosal Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Oral Transmucosal Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Oral Transmucosal Drugs market include Access Pharmaceutical Inc., Aquestive Therapeutics, Inc., Bristol-Myers Squibb Company, C.L Pharm, Cure Pharmaceutical, Eisai Co., Ltd., IntelGenx Corp., LTS Lohmann Therapie-Systeme AG and NAL Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Transmucosal Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Oral Transmucosal Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Transmucosal Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Transmucosal Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oral Transmucosal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Oral Transmucosal Drugs sales, projected growth trends, production technology, application and end-user industry.

Oral Transmucosal Drugs Segment by Company

Access Pharmaceutical Inc.
Aquestive Therapeutics, Inc.
Bristol-Myers Squibb Company
C.L Pharm
Cure Pharmaceutical
Eisai Co., Ltd.
IntelGenx Corp.
LTS Lohmann Therapie-Systeme AG
NAL Pharma
Otsuka Pharmaceutical Co., Ltd.
Soligenix
Viatris
ZIM Laboratories Limited
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Oral Transmucosal Drugs Segment by Type

Liquid Spray
Tablets
Gels
Films
Others
Oral Transmucosal Drugs Segment by Application

Cardiovascular Disorders
Diabetes
Acute Pain Managements
Others
Oral Transmucosal Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Oral Transmucosal Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Oral Transmucosal Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oral Transmucosal Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Oral Transmucosal Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Transmucosal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Transmucosal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Transmucosal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Transmucosal Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Transmucosal Drugs industry.
Chapter 3: Detailed analysis of Oral Transmucosal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Oral Transmucosal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Oral Transmucosal Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Oral Transmucosal Drugs Sales Value (2020-2031)
1.2.2 Global Oral Transmucosal Drugs Sales Volume (2020-2031)
1.2.3 Global Oral Transmucosal Drugs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Oral Transmucosal Drugs Market Dynamics
2.1 Oral Transmucosal Drugs Industry Trends
2.2 Oral Transmucosal Drugs Industry Drivers
2.3 Oral Transmucosal Drugs Industry Opportunities and Challenges
2.4 Oral Transmucosal Drugs Industry Restraints
3 Oral Transmucosal Drugs Market by Company
3.1 Global Oral Transmucosal Drugs Company Revenue Ranking in 2024
3.2 Global Oral Transmucosal Drugs Revenue by Company (2020-2025)
3.3 Global Oral Transmucosal Drugs Sales Volume by Company (2020-2025)
3.4 Global Oral Transmucosal Drugs Average Price by Company (2020-2025)
3.5 Global Oral Transmucosal Drugs Company Ranking (2023-2025)
3.6 Global Oral Transmucosal Drugs Company Manufacturing Base and Headquarters
3.7 Global Oral Transmucosal Drugs Company Product Type and Application
3.8 Global Oral Transmucosal Drugs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Oral Transmucosal Drugs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Oral Transmucosal Drugs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Oral Transmucosal Drugs Market by Type
4.1 Oral Transmucosal Drugs Type Introduction
4.1.1 Liquid Spray
4.1.2 Tablets
4.1.3 Gels
4.1.4 Films
4.1.5 Others
4.2 Global Oral Transmucosal Drugs Sales Volume by Type
4.2.1 Global Oral Transmucosal Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Oral Transmucosal Drugs Sales Volume by Type (2020-2031)
4.2.3 Global Oral Transmucosal Drugs Sales Volume Share by Type (2020-2031)
4.3 Global Oral Transmucosal Drugs Sales Value by Type
4.3.1 Global Oral Transmucosal Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Oral Transmucosal Drugs Sales Value by Type (2020-2031)
4.3.3 Global Oral Transmucosal Drugs Sales Value Share by Type (2020-2031)
5 Oral Transmucosal Drugs Market by Application
5.1 Oral Transmucosal Drugs Application Introduction
5.1.1 Cardiovascular Disorders
5.1.2 Diabetes
5.1.3 Acute Pain Managements
5.1.4 Others
5.2 Global Oral Transmucosal Drugs Sales Volume by Application
5.2.1 Global Oral Transmucosal Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Oral Transmucosal Drugs Sales Volume by Application (2020-2031)
5.2.3 Global Oral Transmucosal Drugs Sales Volume Share by Application (2020-2031)
5.3 Global Oral Transmucosal Drugs Sales Value by Application
5.3.1 Global Oral Transmucosal Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Oral Transmucosal Drugs Sales Value by Application (2020-2031)
5.3.3 Global Oral Transmucosal Drugs Sales Value Share by Application (2020-2031)
6 Oral Transmucosal Drugs Regional Sales and Value Analysis
6.1 Global Oral Transmucosal Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Oral Transmucosal Drugs Sales by Region (2020-2031)
6.2.1 Global Oral Transmucosal Drugs Sales by Region: 2020-2025
6.2.2 Global Oral Transmucosal Drugs Sales by Region (2026-2031)
6.3 Global Oral Transmucosal Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Oral Transmucosal Drugs Sales Value by Region (2020-2031)
6.4.1 Global Oral Transmucosal Drugs Sales Value by Region: 2020-2025
6.4.2 Global Oral Transmucosal Drugs Sales Value by Region (2026-2031)
6.5 Global Oral Transmucosal Drugs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Oral Transmucosal Drugs Sales Value (2020-2031)
6.6.2 North America Oral Transmucosal Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Oral Transmucosal Drugs Sales Value (2020-2031)
6.7.2 Europe Oral Transmucosal Drugs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Oral Transmucosal Drugs Sales Value (2020-2031)
6.8.2 Asia-Pacific Oral Transmucosal Drugs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Oral Transmucosal Drugs Sales Value (2020-2031)
6.9.2 South America Oral Transmucosal Drugs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Oral Transmucosal Drugs Sales Value (2020-2031)
6.10.2 Middle East & Africa Oral Transmucosal Drugs Sales Value Share by Country, 2024 VS 2031
7 Oral Transmucosal Drugs Country-level Sales and Value Analysis
7.1 Global Oral Transmucosal Drugs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Oral Transmucosal Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Oral Transmucosal Drugs Sales by Country (2020-2031)
7.3.1 Global Oral Transmucosal Drugs Sales by Country (2020-2025)
7.3.2 Global Oral Transmucosal Drugs Sales by Country (2026-2031)
7.4 Global Oral Transmucosal Drugs Sales Value by Country (2020-2031)
7.4.1 Global Oral Transmucosal Drugs Sales Value by Country (2020-2025)
7.4.2 Global Oral Transmucosal Drugs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.5.2 USA Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Canada Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.8.2 Germany Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.9.2 France Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 France Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Italy Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Spain Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Russia Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.16.2 China Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 China Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.17.2 Japan Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.19.2 India Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 India Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Australia Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Chile Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Peru Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Israel Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.29.2 UAE Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.31.2 Iran Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Oral Transmucosal Drugs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Oral Transmucosal Drugs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Oral Transmucosal Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Access Pharmaceutical Inc.
8.1.1 Access Pharmaceutical Inc. Comapny Information
8.1.2 Access Pharmaceutical Inc. Business Overview
8.1.3 Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.1.4 Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Portfolio
8.1.5 Access Pharmaceutical Inc. Recent Developments
8.2 Aquestive Therapeutics, Inc.
8.2.1 Aquestive Therapeutics, Inc. Comapny Information
8.2.2 Aquestive Therapeutics, Inc. Business Overview
8.2.3 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.2.4 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Portfolio
8.2.5 Aquestive Therapeutics, Inc. Recent Developments
8.3 Bristol-Myers Squibb Company
8.3.1 Bristol-Myers Squibb Company Comapny Information
8.3.2 Bristol-Myers Squibb Company Business Overview
8.3.3 Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.3.4 Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Portfolio
8.3.5 Bristol-Myers Squibb Company Recent Developments
8.4 C.L Pharm
8.4.1 C.L Pharm Comapny Information
8.4.2 C.L Pharm Business Overview
8.4.3 C.L Pharm Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.4.4 C.L Pharm Oral Transmucosal Drugs Product Portfolio
8.4.5 C.L Pharm Recent Developments
8.5 Cure Pharmaceutical
8.5.1 Cure Pharmaceutical Comapny Information
8.5.2 Cure Pharmaceutical Business Overview
8.5.3 Cure Pharmaceutical Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.5.4 Cure Pharmaceutical Oral Transmucosal Drugs Product Portfolio
8.5.5 Cure Pharmaceutical Recent Developments
8.6 Eisai Co., Ltd.
8.6.1 Eisai Co., Ltd. Comapny Information
8.6.2 Eisai Co., Ltd. Business Overview
8.6.3 Eisai Co., Ltd. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.6.4 Eisai Co., Ltd. Oral Transmucosal Drugs Product Portfolio
8.6.5 Eisai Co., Ltd. Recent Developments
8.7 IntelGenx Corp.
8.7.1 IntelGenx Corp. Comapny Information
8.7.2 IntelGenx Corp. Business Overview
8.7.3 IntelGenx Corp. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.7.4 IntelGenx Corp. Oral Transmucosal Drugs Product Portfolio
8.7.5 IntelGenx Corp. Recent Developments
8.8 LTS Lohmann Therapie-Systeme AG
8.8.1 LTS Lohmann Therapie-Systeme AG Comapny Information
8.8.2 LTS Lohmann Therapie-Systeme AG Business Overview
8.8.3 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.8.4 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Portfolio
8.8.5 LTS Lohmann Therapie-Systeme AG Recent Developments
8.9 NAL Pharma
8.9.1 NAL Pharma Comapny Information
8.9.2 NAL Pharma Business Overview
8.9.3 NAL Pharma Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.9.4 NAL Pharma Oral Transmucosal Drugs Product Portfolio
8.9.5 NAL Pharma Recent Developments
8.10 Otsuka Pharmaceutical Co., Ltd.
8.10.1 Otsuka Pharmaceutical Co., Ltd. Comapny Information
8.10.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
8.10.3 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.10.4 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Portfolio
8.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
8.11 Soligenix
8.11.1 Soligenix Comapny Information
8.11.2 Soligenix Business Overview
8.11.3 Soligenix Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.11.4 Soligenix Oral Transmucosal Drugs Product Portfolio
8.11.5 Soligenix Recent Developments
8.12 Viatris
8.12.1 Viatris Comapny Information
8.12.2 Viatris Business Overview
8.12.3 Viatris Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.12.4 Viatris Oral Transmucosal Drugs Product Portfolio
8.12.5 Viatris Recent Developments
8.13 ZIM Laboratories Limited
8.13.1 ZIM Laboratories Limited Comapny Information
8.13.2 ZIM Laboratories Limited Business Overview
8.13.3 ZIM Laboratories Limited Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.13.4 ZIM Laboratories Limited Oral Transmucosal Drugs Product Portfolio
8.13.5 ZIM Laboratories Limited Recent Developments
8.14 GlaxoSmithKline plc
8.14.1 GlaxoSmithKline plc Comapny Information
8.14.2 GlaxoSmithKline plc Business Overview
8.14.3 GlaxoSmithKline plc Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.14.4 GlaxoSmithKline plc Oral Transmucosal Drugs Product Portfolio
8.14.5 GlaxoSmithKline plc Recent Developments
8.15 Teva Pharmaceutical Industries Ltd.
8.15.1 Teva Pharmaceutical Industries Ltd. Comapny Information
8.15.2 Teva Pharmaceutical Industries Ltd. Business Overview
8.15.3 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales, Value and Gross Margin (2020-2025)
8.15.4 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Portfolio
8.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Oral Transmucosal Drugs Value Chain Analysis
9.1.1 Oral Transmucosal Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Oral Transmucosal Drugs Sales Mode & Process
9.2 Oral Transmucosal Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Oral Transmucosal Drugs Distributors
9.2.3 Oral Transmucosal Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.